Tags

Type your tag names separated by a space and hit enter

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
RMD Open. 2020 09; 6(2)RO

Abstract

OBJECTIVES

Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany.

METHODS

Using an online questionnaire (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters-for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection-are documented.

RESULTS

Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course.

CONCLUSIONS

In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.

Authors+Show Affiliations

Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany r.hasseli@kerckhoff-klinik.de.Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany.Department of Rheumatology and Immunology, Saint Josef Hospital, Wuppertal, Germany.Department of Rheumatology and Clinical Immunology, Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin, Berlin, Germany.Department of Rheumatology, University of Heidelberg, Heidelberg, Germany.Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.Department of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Medical Faculty, Duesseldorf, Germany.Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs University of Freiburg, Freiburg, Germany.Department of Internal Medicine III, University Hospital Jena, Jena, Germany.Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany.Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte,Essen, Germany.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32878994

Citation

Hasseli, Rebecca, et al. "National Registry for Patients With Inflammatory Rheumatic Diseases (IRD) Infected With SARS-CoV-2 in Germany (ReCoVery): a Valuable Mean to Gain Rapid and Reliable Knowledge of the Clinical Course of SARS-CoV-2 Infections in Patients With IRD." RMD Open, vol. 6, no. 2, 2020.
Hasseli R, Mueller-Ladner U, Schmeiser T, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020;6(2).
Hasseli, R., Mueller-Ladner, U., Schmeiser, T., Hoyer, B. F., Krause, A., Lorenz, H. M., Regierer, A. C., Richter, J. G., Strangfeld, A., Voll, R. E., Pfeil, A., Schulze-Koops, H., & Specker, C. (2020). National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open, 6(2). https://doi.org/10.1136/rmdopen-2020-001332
Hasseli R, et al. National Registry for Patients With Inflammatory Rheumatic Diseases (IRD) Infected With SARS-CoV-2 in Germany (ReCoVery): a Valuable Mean to Gain Rapid and Reliable Knowledge of the Clinical Course of SARS-CoV-2 Infections in Patients With IRD. RMD Open. 2020;6(2) PubMed PMID: 32878994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. AU - Hasseli,Rebecca, AU - Mueller-Ladner,Ulf, AU - Schmeiser,Tim, AU - Hoyer,Bimba F, AU - Krause,Andreas, AU - Lorenz,Hanns-Martin, AU - Regierer,Anne Constanze, AU - Richter,Jutta G, AU - Strangfeld,Anja, AU - Voll,Reinhard E, AU - Pfeil,Alexander, AU - Schulze-Koops,Hendrik, AU - Specker,Christof, PY - 2020/05/18/received PY - 2020/07/09/revised PY - 2020/08/10/accepted PY - 2020/9/4/entrez PY - 2020/9/4/pubmed PY - 2020/9/18/medline KW - Antirheumatic Agents KW - Autoimmune Diseases KW - Communicable Diseases KW - Epidemiology KW - Health services research KW - Imported JF - RMD open JO - RMD Open VL - 6 IS - 2 N2 - OBJECTIVES: Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany. METHODS: Using an online questionnaire (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters-for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection-are documented. RESULTS: Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course. CONCLUSIONS: In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic. SN - 2056-5933 UR - https://www.unboundmedicine.com/medline/citation/32878994/National_registry_for_patients_with_inflammatory_rheumatic_diseases__IRD__infected_with_SARS_CoV_2_in_Germany__ReCoVery_:_a_valuable_mean_to_gain_rapid_and_reliable_knowledge_of_the_clinical_course_of_SARS_CoV_2_infections_in_patients_with_IRD_ DB - PRIME DP - Unbound Medicine ER -